Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
出版年份 2018 全文链接
标题
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
作者
关键词
-
出版物
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-04-07
DOI
10.1002/hon.2509
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
- (2017) Francesca Palandri et al. Oncotarget
- Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis
- (2017) Marco Romano et al. OncoImmunology
- Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
- (2016) Nicola Polverelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib
- (2016) Joanna von Hofsten et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms
- (2015) Sowmya Parampalli Yajnanarayana et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study
- (2015) Malin Hultcrantz et al. JOURNAL OF CLINICAL ONCOLOGY
- Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function
- (2015) F Perner et al. LEUKEMIA
- Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis
- (2015) F Palandri et al. LEUKEMIA
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
- (2014) Francesca Palandri et al. ANNALS OF HEMATOLOGY
- Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment
- (2014) Lana X. Tong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
- (2013) Roger A. Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
- (2012) Robyn M. Emanuel et al. JOURNAL OF CLINICAL ONCOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting
- (2008) Teresa C. Horan et al. AMERICAN JOURNAL OF INFECTION CONTROL
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
- (2008) Ben De Pauw et al. CLINICAL INFECTIOUS DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started